Genentech To Resubmit Avastin sBLA In Mid-2007
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.